Voltar
Artigo Acesso aberto Revisado por pares
BIBTEX RIS

Rationale and Design of the IROCAS Study: Multicenter, International, Randomized Phase 3 Trial Comparing Adjuvant Modified (m) FOLFIRINOX to mFOLFOX6 in Patients With High-Risk Stage III (pT4 and/or N2) Colon Cancer—A UNICANCER GI-PRODIGE Trial

2018; Elsevier BV; Volume: 18; Issue: 1 Linguagem: Inglês

10.1016/j.clcc.2018.09.011

ISSN

1938-0674

Autores

Jaafar Bennouna, Thierry André, L. Campion, Sandrine Hiret, Laurent Miglianico, Laurent Mineur, Yann Touchefeu, Pascal Artru, Timothy R. Asmis, Olivier Bouché, Florence Borde, Petr Kavan, You-Heng Lam, Laetitia-Shana Rajpar, Jean‐François Emile, C. Jouffroy, Sharlene Gill, Julien Taı̈eb,

Tópico(s)

Gastric Cancer Management and Outcomes

Resumo

According to the IDEA trial, 6-month adjuvant chemotherapy should remain the treatment standard in stage III T4 or N2 colon cancer. The relatively poor survival in this high-risk subgroup-a 3-year disease-free survival (DFS) rate of 65%-and the potential synergistic efficacy of 5-fluorouracil (5-FU), oxaliplatin, and irinotecan suggest that FOLFIRINOX may be a regimen of particular interest in this setting.

Referência(s)